This new generation of molecules, which display high selectivity and specificity, good tolerance, and bioavailability, has considerably enriched the pharmacological toolbox to study SHP2 pathophysiological functions, highlighting the therapeutic potential for inflammatory diseases and cancer in preclinical models. The gene discussed is PTPN11; the disease is cancer.